Cargando…

Risk of cardiovascular events after initiation of long-acting bronchodilators in patients with chronic obstructive lung disease: A population-based study

OBJECTIVES: Long-acting bronchodilators are mainstay treatment for moderate to severe chronic obstructive pulmonary disease. A growing body of evidence indicates an increased risk of cardiovascular events upon initiation of these medications. We hypothesize that this risk is higher in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aljaafareh, Almotasembellah, Valle, Jose Ruben, Lin, Yu-Li, Kuo, Yong-Fang, Sharma, Gulshan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052927/ https://www.ncbi.nlm.nih.gov/pubmed/27757229 http://dx.doi.org/10.1177/2050312116671337

Ejemplares similares

Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD
por: Bishwakarma, Raju, et al.
Publicado: (2017)

Risk of adverse cardiovascular events with use of inhaled long-acting bronchodilators in management of chronic obstructive pulmonary disease
por: Wang, Meng-Ting, et al.
Publicado: (2019)

Long-acting Inhaled Bronchodilator and Risk of Vascular Events in Patients With Chronic Obstructive Pulmonary Disease in Taiwan Population
por: Tsai, Ming-Jun, et al.
Publicado: (2015)

Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy
por: Bengtson, Lindsay G.S., et al.
Publicado: (2018)

Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease
por: Donohue, James F, et al.
Publicado: (2011)

A Rare Case of Raoultella planticola Pneumonia: An Emerging Pathogen
por: Westerveld, Donevan, et al.
Publicado: (2017)

Long-acting Inhaled Bronchodilator and Risk of Vascular Events in Patients With Chronic Obstructive Pulmonary Disease in Taiwan Population: Erratum
Publicado: (2016)

V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results
por: Devillier, Philippe, et al.
Publicado: (2015)

The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease
por: Kliber, Agnes, et al.
Publicado: (2010)

Major comorbidities lead to the risk of adverse cardiovascular events in chronic obstructive pulmonary disease patients using inhaled long-acting bronchodilators: a case-control study
por: Chen, Yen-Fu, et al.
Publicado: (2019)

Comparison of efficacy of long-acting bronchodilators in emphysema dominant and emphysema nondominant chronic obstructive pulmonary disease
por: Fujimoto, Keisaku, et al.
Publicado: (2011)

Prescribing Patterns for Long-Acting Inhaled Bronchodilators Among Rural Adults With Chronic Obstructive Pulmonary Disease
por: Brunner, Wendy M., et al.
Publicado: (2022)

The paradoxical response to short-acting bronchodilator administration in patients with chronic obstructive pulmonary disease
por: Shin, Hong-Joon, et al.
Publicado: (2021)

Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?
por: Price, David, et al.
Publicado: (2014)

Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease
por: Roberts, Melissa H., et al.
Publicado: (2019)

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
por: Kang, Jieun, et al.
Publicado: (2017)

Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids
por: Asche, Carl Victor, et al.
Publicado: (2012)

Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis
por: Naya, Ian, et al.
Publicado: (2019)

Severity Staging of Chronic Obstructive Pulmonary Disease: Differences in Pre- and Post-Bronchodilator Spirometry
por: Lin, Sheng-Hsiang, et al.
Publicado: (2009)

Short-acting bronchodilators for the management of acute exacerbations of chronic obstructive pulmonary disease in the hospital setting: systematic review
por: Kopsaftis, Zoe A., et al.
Publicado: (2018)

Short Term Effects of Tiotropium on COPD Patients Treated with Long Acting Bronchodilators
por: Nicolini, Antonello
Publicado: (2012)

Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2013)

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
por: Matera, Maria Gabriella, et al.
Publicado: (2015)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

Risk of Pneumonia with Inhaled Corticosteroid versus Long-Acting Bronchodilator Regimens in Chronic Obstructive Pulmonary Disease: A New-User Cohort Study
por: DiSantostefano, Rachael L., et al.
Publicado: (2014)

Erratum: Triple Therapy versus Dual or Monotherapy with Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis
Publicado: (2021)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care
por: Punekar, Yogesh Suresh, et al.
Publicado: (2015)

Cardiovascular morbidity and the use of inhaled bronchodilators
por: Macie, Christine, et al.
Publicado: (2008)

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2013)

The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease
por: Beeh, Kai M.
Publicado: (2016)

Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives
por: Rhee, Chin Kook, et al.
Publicado: (2019)

Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator
por: Chin, Pik-Qi, et al.
Publicado: (2022)

Characteristics of Patients with Chronic Obstructive Pulmonary Disease Treated with Long-Acting Bronchodilators in a Real-World Setting in Singapore: A Single-Center Observational Study
por: Sim, Marcus, et al.
Publicado: (2022)

Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial
por: Haney, Sarah, et al.
Publicado: (2005)

A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD
por: Jara, Michele, et al.
Publicado: (2012)

Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
por: Halpin, David M. G., et al.
Publicado: (2016)

Bronchodilation improves endurance but not muscular efficiency in chronic obstructive pulmonary disease
por: van der Vaart, Hester, et al.
Publicado: (2011)

Bronchodilator Response Assessment of the Small Airways Obstructive Pattern
por: Bokov, Plamen, et al.
Publicado: (2017)

Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study
por: Tan, Wan C, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_luqj2foj1l0jrghfijfou95ihf